5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Metrics: PDF 713 views | HTML 1560 views | ?
Federica Cappuccini1, Emily Pollock1, Stephen Stribbling1, Adrian V.S. Hill1 and Irina Redchenko1
1The Jenner Institute, University of Oxford, Roosevelt Drive Oxford, Oxford OX3 7DQ, United Kingdom
Irina Redchenko, email: firstname.lastname@example.org
Keywords: cancer, viral vectored vaccine, 5T4 oncofoetal antigen, immunogenicity, immune checkpoint blockade
Received: March 21, 2017 Accepted: April 19, 2017 Published: May 07, 2017
The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attributable primarily to CD8+ T cells. By comparison, homologous MVA vaccination regimen did not induce detectable 5T4-specific T cell responses. ChAdOx1-MVA vaccinated mice were completely protected against subsequent B16 melanoma challenge, but in therapeutic settings this regime was only modestly effective in delaying tumour outgrowth. Concomitant delivery of the vaccine with monoclonal antibodies (mAbs) targeting immune checkpoint regulators LAG-3, PD-1 or PD-L1 demonstrated that the combination of vaccine with anti PD-1 mAb could significantly delay tumour growth and increase overall survival of tumour-bearing mice. Our findings support a translation of the combinatorial approach based on the heterologous ChAdOx1-MVA vaccination platform with immune checkpoint blockade into the clinic for the treatment of 5T4-positive tumours such as prostate, renal, colorectal, gastric, ovarian, lung cancer and mesothelioma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.